Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 10.27
DVAX's Cash to Debt is ranked lower than
57% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. DVAX: 10.27 )
Ranked among companies with meaningful Cash to Debt only.
DVAX' s 10-Year Cash to Debt Range
Min: 2.34  Med: 10000.00 Max: No Debt
Current: 10.27
Equity to Asset 0.67
DVAX's Equity to Asset is ranked lower than
52% of the 594 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. DVAX: 0.67 )
Ranked among companies with meaningful Equity to Asset only.
DVAX' s 10-Year Equity to Asset Range
Min: -2.28  Med: 0.74 Max: 0.93
Current: 0.67
-2.28
0.93
F-Score: 1
Z-Score: 3.41
M-Score: -4.30
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -1271.85
DVAX's Operating margin (%) is ranked lower than
81% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. DVAX: -1271.85 )
Ranked among companies with meaningful Operating margin (%) only.
DVAX' s 10-Year Operating margin (%) Range
Min: -2150.61  Med: -547.70 Max: -37.49
Current: -1271.85
-2150.61
-37.49
Net-margin (%) -1263.31
DVAX's Net-margin (%) is ranked lower than
81% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. DVAX: -1263.31 )
Ranked among companies with meaningful Net-margin (%) only.
DVAX' s 10-Year Net-margin (%) Range
Min: -2100.73  Med: -509.28 Max: -56.15
Current: -1263.31
-2100.73
-56.15
ROE (%) -82.92
DVAX's ROE (%) is ranked lower than
76% of the 761 Companies
in the Global Biotechnology industry.

( Industry Median: -29.50 vs. DVAX: -82.92 )
Ranked among companies with meaningful ROE (%) only.
DVAX' s 10-Year ROE (%) Range
Min: -307.22  Med: -66.96 Max: -30.62
Current: -82.92
-307.22
-30.62
ROA (%) -67.44
DVAX's ROA (%) is ranked lower than
78% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -25.57 vs. DVAX: -67.44 )
Ranked among companies with meaningful ROA (%) only.
DVAX' s 10-Year ROA (%) Range
Min: -85.08  Med: -52.00 Max: -19.74
Current: -67.44
-85.08
-19.74
ROC (Joel Greenblatt) (%) -1255.27
DVAX's ROC (Joel Greenblatt) (%) is ranked lower than
64% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -333.14 vs. DVAX: -1255.27 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
DVAX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2870.62  Med: -956.94 Max: -172.67
Current: -1255.27
-2870.62
-172.67
Revenue Growth (3Y)(%) -37.60
DVAX's Revenue Growth (3Y)(%) is ranked lower than
79% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. DVAX: -37.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
DVAX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: -27.45 Max: 88.1
Current: -37.6
0
88.1
EBITDA Growth (3Y)(%) -1.90
DVAX's EBITDA Growth (3Y)(%) is ranked higher than
52% of the 427 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. DVAX: -1.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
DVAX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -63.4  Med: -16.10 Max: 39.1
Current: -1.9
-63.4
39.1
EPS Growth (3Y)(%) -3.80
DVAX's EPS Growth (3Y)(%) is ranked higher than
54% of the 413 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. DVAX: -3.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
DVAX' s 10-Year EPS Growth (3Y)(%) Range
Min: -60.6  Med: -20.35 Max: 26
Current: -3.8
-60.6
26
» DVAX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

DVAX Guru Trades in Q2 2014

Jim Simons 1,139,293 sh (New)
» More
Q3 2014

DVAX Guru Trades in Q3 2014

Jim Simons 131,694 sh (-88.44%)
» More
Q4 2014

DVAX Guru Trades in Q4 2014

Jim Simons Sold Out
» More
Q1 2015

DVAX Guru Trades in Q1 2015

Jim Simons 59,051 sh (New)
Chuck Royce 260,000 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with DVAX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 11.01
DVAX's P/B is ranked lower than
79% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. DVAX: 11.01 )
Ranked among companies with meaningful P/B only.
DVAX' s 10-Year P/B Range
Min: 0.65  Med: 4.03 Max: 14.93
Current: 11.01
0.65
14.93
P/S 92.10
DVAX's P/S is ranked lower than
86% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 11.60 vs. DVAX: 92.10 )
Ranked among companies with meaningful P/S only.
DVAX' s 10-Year P/S Range
Min: 0.18  Med: 19.29 Max: 92.84
Current: 92.1
0.18
92.84
Current Ratio 4.97
DVAX's Current Ratio is ranked higher than
54% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. DVAX: 4.97 )
Ranked among companies with meaningful Current Ratio only.
DVAX' s 10-Year Current Ratio Range
Min: 1.87  Med: 5.94 Max: 13.98
Current: 4.97
1.87
13.98
Quick Ratio 4.97
DVAX's Quick Ratio is ranked higher than
56% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. DVAX: 4.97 )
Ranked among companies with meaningful Quick Ratio only.
DVAX' s 10-Year Quick Ratio Range
Min: 1.87  Med: 5.94 Max: 13.98
Current: 4.97
1.87
13.98
Days Sales Outstanding 40.65
DVAX's Days Sales Outstanding is ranked higher than
70% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. DVAX: 40.65 )
Ranked among companies with meaningful Days Sales Outstanding only.
DVAX' s 10-Year Days Sales Outstanding Range
Min: 8.1  Med: 57.91 Max: 187.36
Current: 40.65
8.1
187.36

Valuation & Return

vs
industry
vs
history
Price/Net Cash 13.66
DVAX's Price/Net Cash is ranked lower than
66% of the 451 Companies
in the Global Biotechnology industry.

( Industry Median: 8.40 vs. DVAX: 13.66 )
Ranked among companies with meaningful Price/Net Cash only.
DVAX' s 10-Year Price/Net Cash Range
Min: 1.81  Med: 5.20 Max: 26.38
Current: 13.66
1.81
26.38
Price/Net Current Asset Value 12.75
DVAX's Price/Net Current Asset Value is ranked lower than
65% of the 538 Companies
in the Global Biotechnology industry.

( Industry Median: 7.59 vs. DVAX: 12.75 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
DVAX' s 10-Year Price/Net Current Asset Value Range
Min: 1.75  Med: 4.65 Max: 124
Current: 12.75
1.75
124
Price/Tangible Book 11.33
DVAX's Price/Tangible Book is ranked lower than
72% of the 687 Companies
in the Global Biotechnology industry.

( Industry Median: 5.90 vs. DVAX: 11.33 )
Ranked among companies with meaningful Price/Tangible Book only.
DVAX' s 10-Year Price/Tangible Book Range
Min: 1.69  Med: 4.15 Max: 27.84
Current: 11.33
1.69
27.84
Price/Median PS Value 4.77
DVAX's Price/Median PS Value is ranked lower than
91% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. DVAX: 4.77 )
Ranked among companies with meaningful Price/Median PS Value only.
DVAX' s 10-Year Price/Median PS Value Range
Min: 0.03  Med: 0.75 Max: 3.75
Current: 4.77
0.03
3.75
Earnings Yield (Greenblatt) (%) -13.73
DVAX's Earnings Yield (Greenblatt) (%) is ranked lower than
72% of the 813 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. DVAX: -13.73 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
DVAX' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -13.73  Med: 58.95 Max: 3563.3
Current: -13.73
-13.73
3563.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:DYF1.Germany,
Dynavax Technologies Corp was incorporated in California in August 1996 under the name Double Helix Corporation, and it changed its name to Dynavax Technologies Corporation in September 1996. The Company reincorporated in Delaware in 2000. The Company is a clinical-stage biopharmaceutical company. It discovers and develops novel products to prevent and treat infectious and inflammatory diseases. The Company's product candidate is HEPLISAVTM, a Phase 3 investigational adult hepatitis B vaccine. Its pipeline of product candidates includes: HEPLISAV, its autoimmune program partnered with GlaxoSmithKline, and its therapy for asthma partnered with AstraZeneca AB. Its product candidates are based on the use of immunostimulatory and immunoregulatory sequences. HEPLISAV is an investigational adult hepatitis B vaccine. In Phase 3 trials, HEPLISAV demonstrated higher and earlier protection with fewer doses than currently licensed vaccines. The Company has worldwide commercial rights to HEPLISAV. HEPLISAV combines its first generation 1018 ISS with hepatitis B surface antigen manufactured in its facility in Düsseldorf, Germany. The Company competes with pharmaceutical companies, biotechnology companies, academic institutions and research organizations, in developing therapies to prevent or treat infectious diseases and inflammatory and autoimmune diseases. Any product candidate it develops is subject to extensive regulation by federal, state and local governmental authorities in the United States, including the FDA and foreign regulatory agencies.
» More Articles for NAS:DVAX

Headlines

Articles On GuruFocus.com
Dynavax Prices Public Offering of Common Stock Jul 22 2015 
Dynavax Announces Proposed Public Offering of Common Stock Jul 21 2015 
Dynavax Secures $40 Million Credit Facility With Hercules Technology Growth Capital Dec 29 2014 
William Blair’s Top BioPharmaceutical Stock Picks for Q1 2015 Dec 23 2014 
Dynavax Announces Webcast of R&D Day Dec 09 2014 
Dynavax and AstraZeneca to Advance TLR9 Agonist for Treatment of Asthma Into Phase 2a Clinical Study Dec 08 2014 
Dynavax Regains Full Rights to Investigational TLR 7/9 Inhibitor DV1179 Following Expiration of Coll Nov 28 2014 
Dynavax Announces Independent DSMB Recommendation to Continue Phase 3 Study of HEPLISAV-B(TM) Nov 10 2014 
Dynavax Reports Third Quarter 2014 Financial Results Nov 05 2014 
Dynavax Announces Resignation of Dino Dina From Board of Directors Oct 15 2014 

More From Other Websites
DYNAVAX TECHNOLOGIES CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Jul 22 2015
Dynavax Prices Public Offering of Common Stock Jul 22 2015
Dynavax Prices Public Offering of Common Stock Jul 22 2015
Dynavax Announces Proposed Public Offering of Common Stock Jul 21 2015
Dynavax Announces Proposed Public Offering of Common Stock Jul 21 2015
DYNAVAX TECHNOLOGIES CORP Files SEC form 8-K, Results of Operations and Financial Condition, Other... Jul 09 2015
Trending Now: Dynavax Technologiesn Jul 09 2015
Dynavax Announces Third Independent DSMB Recommendation to Continue Phase 3 Study of HEPLISAV-B(TM)... Jul 09 2015
Dynavax Announces Third Independent DSMB Recommendation to Continue Phase 3 Study of HEPLISAV-B(TM)... Jul 09 2015
Dynavax Technologies (DVAX) in Focus: Stock Up 8.2% - Tale of the Tape Jul 07 2015
4 Big-Volume Stocks to Trade for Breakouts Jul 07 2015
RA Capital Is Expecting A Breakthrough Cancer Drug From This Biotech Jun 29 2015
Dynavax to Present at the William Blair 35th Annual Growth Stock Health Care Conference Jun 09 2015
Dynavax to Present at the William Blair 35th Annual Growth Stock Health Care Conference Jun 09 2015
Merck's Keytruda under Priority Review for Lung Cancer - Analyst Blog Jun 02 2015
DYNAVAX TECHNOLOGIES CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 01 2015
Merck and Dynavax Announce New Collaboration Investigating the Combination of Immuno-Oncology... Jun 01 2015
DYNAVAX TECHNOLOGIES CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 28 2015
DYNAVAX TECHNOLOGIES CORP Financials May 15 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK